QIAGEN and Digene Merged to Fight Cervical Cancer

Two of the world’s leading companies in molecular diagnostics have joined forces to create the market and technology leader in molecular diagnostics. The acquisition brings together QIAGEN’s unique portfolio in sample and assay technologies, including the broadest panel of molecular diagnostic tests, with Digene’s leadership in HPV. This strategic transaction will accelerate growth and further advancements in women’s health and molecular diagnostics.

HPV causes cervical cancer, the second biggest cause of female cancer mortality worldwide. Reliable diagnosis with the HPV test, the first FDA-approved and CE-marked test for HPV, contributes to preventing millions of women worldwide to be exposed to what is today’s most avoidable cancer.